Trials of Sangamo's gene therapy called SB-525 show promising results in animals with hemophilia A.
WILATE®, a human-derived von Willebrand factor/coagulation factor VIII therapy, will be used in two upcoming clinical trials slated to launch in December 2016.
Gene editing therapy will be used in clinical trials first in people with hemophilia B, then in those with hemophilia A.
The program encourages innovative research and educational initiatives that benefit individuals with hemophilia worldwide.
Preliminary findings show psychosocial impact on individuals and families dealing with hemophlia B, including mild and moderate forms.
Encouraging results from a phase I/II clinical trial of SPK-9001, the company’s novel investigational hemophilia B gene therapy.
Preliminary data from a low-dose group were presented at the 21st Congress of the European Hematology Association in Copenhagen, Denmark.
Combined company is expected to be the global leader in the treatment of many rare diseases.
Chugai's novel prophylactic therapy for people with hemophilia A is administered through a subcutaneous injection.
Gene therapy trials in lab animals show significant increases in production of factor VIII and IX.
eNewsletter Sign Up
Steps for Living
Victory for Women
Unite for Bleeding Disorders Walk
Donate Your Car